Highly selective CXCR4 chemokine receptor antagonist (IC50
values are 0.02 - 0.13 and > 25 μ
M for CXCR4 and all other chemokine receptors respectively). Switches inflammatory responses from Th2 to Th1 type and reduces airway hyperresponsiveness in a mouse model of asthma. Potently inhibits HIV-1 and HIV-2 replication in vitro
= 4 - 35 nM) and mobilizes hematopoietic stem cells in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibits HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.
Bridger et al.
The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease.
Hogaboam et al.
Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi et al.
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
Hatse et al.
FEBS Letts., 2002;527:255
The citations listed below are publications that use Tocris products. Selected citations for AMD 3100 octahydrochloride include:
Showing Results 1 - 9 of 9